Sumitomo Pharma Co.Ltd.

As of March 31, 2025, DAI Nippon Pharmaceutical carries a market capitalization of 1.90B, placing it among publicly traded companies globally. Its enterprise value stands at 3.68B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

DAI Nippon Pharmaceutical 's next confirmed earnings release is scheduled for October 30, 2026.

As of March 31, 2025, DAI Nippon Pharmaceutical has 397.29M shares outstanding.

These figures are as of March 31, 2025.

As of March 31, 2025, DAI Nippon Pharmaceutical maintains a current ratio of 1.05, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2025.

Over the twelve months ended March 31, 2025, DAI Nippon Pharmaceutical recorded an income tax benefit of -138.06M rather than an expense, typically from losses, carryforwards, or the release of a tax provision.

As of the close on September 16, 2026, DAI Nippon Pharmaceutical 's stock has declined approximately 15.46% over the past 52 weeks. The 50-day moving average sits at 12.72, while the 200-day moving average is 9.34.

As of March 31, 2025, DAI Nippon Pharmaceutical holds 266.57M in cash and equivalents against 2.04B in total debt, resulting in a net debt position of 1.88B. Total book value stands at 1.13B, with working capital of 83.83M providing operational flexibility.

These figures cover the twelve months ended March 31, 2025.

DAI Nippon Pharmaceutical 's most recent stock split took place on March 26, 1992 with a 20:21 split ratio.